Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CAI

Caris Life Sciences Inc

May 12 • 04:00PM ET

16.76

+0.82 5.14 %

Healthcare • Biotechnology • USA • Mid • NASD

May 11, 12:20 PMCaris Life Sciences real-world study validates ultra-deep whole exome tumor mutational burden assay as superior predictor of pembrolizumab benefit vs targeted panels

Peers: TEM GH TXG NTRA NEO

| Held by: VTI VB VBK IBB IWR IWP IDNA IWF IWD VONG

Index	-	P/E	-	EPS (ttm)	-1.47	Insider Own	57.52%	Shs Outstand	282.65M	Perf Week	-11.56%
Market Cap	4.74B	Forward P/E	45.37	EPS next Y	0.37	Insider Trans	-0.02%	Shs Float	120.03M	Perf Month	-12.39%
Enterprise Value	4.35B	PEG	-	EPS next Q	0.01	Inst Own	46.94%	Short Float	10.61%	Perf Quarter	-24.40%
Income	-411.43M	P/S	5.22	EPS this Y	134.99%	Inst Trans	24.71%	Short Ratio	5.30	Perf Half Y	-34.56%
Sales	907.29M	P/B	7.98	EPS next Y	159.23%	ROA	4.67%	Short Interest	12.73M	Perf YTD	-37.88%
Book/sh	2.10	P/C	5.75	EPS next 5Y	-	ROE	28.35%	52W High	42.50 -60.56%	Perf Year	-
Cash/sh	2.91	P/FCF	40.93	EPS past 3/5Y	-7.57% -	ROIC	3.34%	52W Low	15.70 6.75%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	33.68	Sales past 3/5Y	62.87% -	Gross Margin	68.72%	Volatility	6.88% 5.35%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.79	EPS Y/Y TTM	-10.99%	Oper. Margin	11.94%	ATR (14)	1.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.52	Sales Y/Y TTM	100.51%	Profit Margin	-45.35%	RSI (14)	40.00	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	7.05	EPS Q/Q	99.60%	SMA20	-12.74%	Beta	-	Target Price	28.00
Payout	-	Debt/Eq	0.73	Sales Q/Q	78.78%	SMA50	-11.40%	Rel Volume	1.15	Prev Close	15.94
Employees	1846	LT Debt/Eq	0.72	Earnings	May 07 AMC	SMA200	-35.82%	Avg Volume	2.40M	Price	16.76
IPO	Jun 18, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	100.00% 3.23%	Trades		Volume	2,772,973	Change	5.14%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Initiated	Jefferies	Buy	$28
Apr-10-26	Initiated	Piper Sandler	Neutral	$21
Apr-01-26	Initiated	Goldman	Buy	$27
Feb-17-26	Initiated	Robert W. Baird	Outperform	$26
Dec-02-25	Initiated	Canaccord Genuity	Hold	$28
Jul-14-25	Initiated	Wolfe Research	Outperform	$32
Jul-14-25	Initiated	TD Cowen	Buy	$32
Jul-14-25	Initiated	JP Morgan	Overweight	$31
Jul-14-25	Initiated	Guggenheim	Buy	$32
Jul-14-25	Initiated	Evercore ISI	Outperform	$33
Jul-14-25	Initiated	Citigroup	Buy	$34
Jul-14-25	Initiated	BTIG Research	Buy	$38
Jul-14-25	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

May-11-26 12:15PM	Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels (PR Newswire)
May-08-26 04:05PM	Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization (PR Newswire) -18.60%
May-07-26 04:05PM	Caris Life Sciences Reports First Quarter 2026 Financial Results (PR Newswire)
May-05-26 08:30AM	Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis (PR Newswire)
May-04-26 08:30AM	Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies (PR Newswire)
08:30AM	Loading…
Apr-29-26 08:30AM	Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients (PR Newswire)
Apr-24-26 08:30AM	Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
Apr-20-26 08:30AM	Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026 (PR Newswire)
Apr-17-26 08:30AM	Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center (PR Newswire)
Apr-15-26 08:30AM	Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients (PR Newswire)
Apr-08-26 08:30AM	Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients (PR Newswire)
Apr-02-26 08:30AM	Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies (PR Newswire)
Mar-31-26 06:00PM	Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect (PR Newswire) +6.11% +6.99%
Mar-26-26 08:30AM	Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer (PR Newswire)
Mar-25-26 08:30AM	Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 (PR Newswire)
08:30AM	Loading…
Mar-24-26 08:30AM	Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month (PR Newswire)
Mar-20-26 08:30AM	Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients (PR Newswire)
Mar-16-26 08:30AM	Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer (PR Newswire)
Mar-11-26 08:30AM	Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting (PR Newswire)
Mar-09-26 08:30AM	Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer (PR Newswire)
Mar-03-26 11:40AM	BTSG vs. CAI: Which Stock Is the Better Value Option? (Zacks) -6.20%
Feb-28-26 08:00PM	Caris Life Sciences Inc (CAI) Q4 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Feb-27-26 04:40PM	Stocks Settle Lower as Bank Shares Tumble and Tech Stocks Fall (Barchart)
11:14AM	Stocks Retreat on AI Disruption Concerns and Geopolitical Risks (Barchart)
10:07AM	Stocks Fall on AI Fears and Stronger-Than-Expected Producer Prices (Barchart)
07:00AM	Cancer Test Maker Caris Life Sciences Unveils Breakthrough In Early Cancer Detection, Profit Surprise (Benzinga)
03:41AM	Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report (Insider Monkey)
Feb-26-26 10:07PM	Caris Life Sciences Q4 Earnings Call Highlights (MarketBeat) +5.08%
06:00PM	Caris Life Sciences Completes Interim Readout of Achieve 1 Study (PR Newswire)
04:05PM	Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook (PR Newswire)
01:58AM	Loading…
Feb-25-26 01:58AM	Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating (Insider Monkey)
Feb-24-26 08:30AM	Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug (PR Newswire)
Feb-23-26 08:30AM	Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference (PR Newswire) -9.68%
Feb-20-26 01:21PM	Russell 2000 Drop, EM Stocks Hit Records After Court's Tariff Ruling: What's Moving Markets Friday? (Benzinga) -6.33%
Feb-09-26 08:30AM	Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26 (PR Newswire)
Jan-28-26 08:30AM	Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan (PR Newswire)
Jan-12-26 12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga) -10.21%
08:30AM	Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results (PR Newswire)
08:00AM	Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect (PR Newswire)
Jan-05-26 08:30AM	Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-25 08:30AM	The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute (PR Newswire)
Dec-16-25 08:30AM	Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need (PR Newswire)
Dec-08-25 09:55AM	Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-04-25 08:30AM	Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium (PR Newswire)
Dec-02-25 01:53PM	IP Oh No? Recent Stock Market Debuts Have Fizzled. (Barrons.com)
08:30AM	The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute (PR Newswire)
Nov-21-25 08:30AM	Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class (PR Newswire)
Nov-17-25 08:30AM	Caris Life Sciences to Attend Q4 2025 Investor Conferences (PR Newswire)
Nov-05-25 04:05PM	Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (PR Newswire) -6.32% -15.75%
Nov-04-25 07:27AM	What To Expect From Caris Life Sciences Inc (CAI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 08:41AM	Caris Life Sciences announces collaborative new research on TET2 (TipRanks) +5.91%
Oct-29-25 08:30AM	Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response (PR Newswire)
Oct-23-25 08:30AM	Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025 (PR Newswire) +5.39%
Oct-14-25 08:30AM	Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025 (PR Newswire)
Oct-01-25 01:43PM	Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue (Insider Monkey)
Sep-18-25 08:40AM	Strong Performance Lifted Caris Life Sciences (CAI) in Q2 (Insider Monkey)
Sep-11-25 11:17AM	Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test (Insider Monkey)
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)
Aug-15-25 08:30AM	Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek (PR Newswire)
Aug-13-25 08:30AM	New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups (PR Newswire) +5.61%
Aug-12-25 04:05PM	Caris Life Sciences Reports Second Quarter 2025 Financial Results (PR Newswire) +7.45%
Aug-06-25 08:30AM	Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor (PR Newswire)
Aug-05-25 08:30AM	Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed (PR Newswire)
Jul-23-25 08:30AM	Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-22-25 08:30AM	Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis (PR Newswire) +7.07%
Jul-08-25 06:30AM	Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection (PR Newswire)
Jun-20-25 05:01AM	Caris Life Sciences indicated to open at $30, IPO priced at $21 per share (TipRanks)
Jun-18-25 02:50PM	This 'AI TechBio' company goes public as IPO demand spreads to biotech (MarketWatch)
01:37PM	The IPO Market Extends Its Comeback (Barrons.com)

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vacirca Jeff L	Director	May 11 '26	Buy	16.15	31,050	501,426	49,671	May 12 08:22 AM
CASTLEMAN PETER M	Director	Jan 09 '26	Option Exercise	18.60	2,500	46,500	18,629	Jan 13 06:37 PM
Power Luke Thomas	See Remarks	Dec 11 '25	Option Exercise	2.44	62,250	151,890	161,821	Dec 12 07:39 PM
Power Luke Thomas	See Remarks	Dec 11 '25	Sale	26.58	62,250	1,654,461	99,571	Dec 12 07:39 PM
LUKE POWER	Officer	Dec 11 '25	Proposed Sale	27.10	62,250	1,686,975		Dec 11 04:27 PM
Denton John Russel	See Remarks	Nov 07 '25	Buy	24.09	4,184	100,793	9,184	Nov 10 08:12 AM
Spetzler David Baxley	President	Nov 07 '25	Buy	23.85	400	9,540	460,777	Nov 10 08:11 AM
PHILLIPS T DANNY	Director	Sep 11 '25	Option Exercise	2.44	100,000	244,000	116,129	Sep 12 04:29 PM
POSTE GEORGE	Director	Aug 11 '25	Option Exercise	2.44	125,000	305,000	359,754	Aug 13 08:07 PM
Spetzler David Baxley	President	Jun 20 '25	Option Exercise	2.44	75,000	183,000	558,668	Jun 23 06:41 PM
Denton John Russel	See Remarks	Jun 20 '25	Buy	21.00	7,500	157,500	123,591	Jun 23 06:34 PM
Brille Brian J	See Remarks	Jun 20 '25	Buy	21.00	30,000	630,000	162,428	Jun 23 06:30 PM

ASRT Assertio Holdings Inc daily Stock Chart

Peers: OMER XERS HROW FENC ANIP

| Held by: VTI VXF BSVO AVSC DFAS

Index	-	P/E	-	EPS (ttm)	-5.73	Insider Own	2.44%	Shs Outstand	6.45M	Perf Week	1.76%
Market Cap	145.72M	Forward P/E	59.87	EPS next Y	0.38	Insider Trans	-5.39%	Shs Float	6.29M	Perf Month	25.14%
Enterprise Value	114.46M	PEG	-	EPS next Q	-0.17	Inst Own	33.44%	Short Float	4.60%	Perf Quarter	93.07%
Income	-35.69M	P/S	1.43	EPS this Y	68.41%	Inst Trans	5.89%	Short Ratio	1.30	Perf Half Y	97.68%
Sales	102.16M	P/B	1.92	EPS next Y	125.15%	ROA	-14.34%	Short Interest	0.29M	Perf YTD	148.62%
Book/sh	11.73	P/C	2.04	EPS next 5Y	-	ROE	-38.76%	52W High	22.58 -0.13%	Perf Year	144.29%
Cash/sh	11.08	P/FCF	-	EPS past 3/5Y	- 21.69%	ROIC	-30.84%	52W Low	8.61 161.90%	Perf 3Y	-80.35%
Dividend Est.	-	EV/EBITDA	29.88	Sales past 3/5Y	-8.75% 2.24%	Gross Margin	44.32%	Volatility	1.48% 0.95%	Perf 5Y	-21.16%
Dividend TTM	-	EV/Sales	1.12	EPS Y/Y TTM	-15.69%	Oper. Margin	-22.27%	ATR (14)	0.53	Perf 10Y	-97.85%
Dividend Ex-Date	-	Quick Ratio	1.57	Sales Y/Y TTM	-14.15%	Profit Margin	-34.94%	RSI (14)	85.27	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.82	EPS Q/Q	-38.05%	SMA20	15.32%	Beta	0.47	Target Price	23.87
Payout	-	Debt/Eq	0.53	Sales Q/Q	-62.50%	SMA50	31.96%	Rel Volume	0.50	Prev Close	22.36
Employees	53	LT Debt/Eq	0.53	Earnings	May 08 BMO	SMA200	72.54%	Avg Volume	223.20K	Price	22.55
IPO	Dec 02, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-39.36% 10.79%	Trades		Volume	110,954	Change	0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Downgrade	H.C. Wainwright	Buy → Neutral	$18
Jul-26-24	Initiated	Maxim Group	Buy	$3
Jul-03-24	Initiated	H.C. Wainwright	Buy	$4
Nov-07-22	Initiated	Lake Street	Buy	$7
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

May-08-26 08:00AM	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer (Business Wire)
May-05-26 09:00AM	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer (Business Wire)
May-04-26 08:00AM	Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics (Business Wire) +17.00%
Apr-21-26 05:00PM	Assertio Provides Update on Garda Therapeutics Tender Process (Business Wire)
Apr-14-26 10:58AM	Are AVNS, LEG, ASRT Obtaining Fair Deals for their Shareholders? (PR Newswire)
04:10PM	Loading…
Apr-08-26 04:10PM	Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN and Additional Products from Assertio (Business Wire)
04:04PM	Assertio Announces Agreement to be Acquired by Garda Therapeutics (Business Wire)
Mar-16-26 11:00PM	Assertio Holdings Inc (ASRT) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +6.20%
08:13PM	Assertio Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
04:30PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Mar-05-26 12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
08:24AM	AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know (Zacks)
Mar-04-26 09:40AM	Is Assertio (ASRT) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-03-26 04:30PM	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 (Business Wire)
09:10AM	Loading…
Mar-02-26 09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-27-26 12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
07:44AM	Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-26 09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
Feb-24-26 11:31AM	SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus (Zacks)
Feb-23-26 10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
Feb-16-26 09:40AM	Are Medical Stocks Lagging Assertio (ASRT) This Year? (Zacks)
Feb-12-26 08:10AM	Zoetis (ZTS) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-06-26 11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks) +9.64%
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:11AM	Loading…
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:55AM	Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-16-26 09:55AM	Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet (Zacks)
Jan-14-26 09:40AM	Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-12-26 04:15PM	Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements (Business Wire) +10.89%
Jan-09-26 01:45PM	Assertio Announces Publication of Rolvedon Same-Day Dosing Clinical Trial (Business Wire)
Dec-22-25 04:30PM	Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split (Business Wire) -9.81%
Nov-11-25 04:01AM	Assertio Holdings Inc (ASRT) Q3 2025 Earnings Call Highlights: Impressive Growth Amid Market ... (GuruFocus.com) +14.89%
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +5.33%
04:41PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance)
04:13PM	Assertio Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-06-25 08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
Oct-28-25 09:15AM	Assertio Announces Leadership Transition (GlobeNewswire)
Sep-23-25 05:04AM	New Strong Sell Stocks for September 23rd (Zacks)
Sep-19-25 06:23AM	New Strong Sell Stocks for September 19th (Zacks) -7.22%
Sep-16-25 04:59AM	New Strong Sell Stocks for September 16th (Zacks)
Sep-15-25 09:00AM	Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN (clobazam) Oral Film, CIV (GlobeNewswire)
Sep-10-25 07:30AM	Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN at upcoming 150th Annual Meeting of the American Neurological Association (GlobeNewswire)
Sep-03-25 08:15AM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 (GlobeNewswire)
Aug-26-25 06:17AM	New Strong Sell Stocks for August 26th (Zacks)
Aug-12-25 03:06AM	Assertio Holdings Inc (ASRT) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +13.85%
Aug-11-25 06:55PM	Assertio (ASRT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:54PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:31AM	Assertio Holdings Inc (ASRT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-06-25 03:41PM	Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors (PR Newswire)
08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-08-25 06:28AM	New Strong Sell Stocks for July 8th (Zacks)
Jun-30-25 06:03AM	New Strong Sell Stocks for June 30th (Zacks)
Jun-25-25 06:26AM	New Strong Sell Stocks for June 25th (Zacks)
Jun-18-25 05:08AM	New Strong Sell Stocks for June 18th (Zacks)
May-19-25 04:10PM	Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025 (GlobeNewswire) +6.77%
May-13-25 05:38AM	Q1 2025 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-09-25 09:48AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-25 08:15AM	Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -6.46%
Apr-07-25 09:17AM	Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? (Zacks) -6.19%
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE)
Mar-20-25 09:10AM	Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 (GlobeNewswire)
Mar-13-25 12:58PM	Q4 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.46%
03:08AM	Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges (GuruFocus.com)
Mar-12-25 04:30PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-05-25 04:05PM	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 (GlobeNewswire) +6.49%
Jan-03-25 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-17-24 08:30AM	Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors (GlobeNewswire)
Dec-13-24 08:00AM	Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study (GlobeNewswire)
Dec-12-24 08:00AM	Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO (GlobeNewswire)
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire)
Nov-15-24 09:00AM	Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio (Business Wire)
Nov-12-24 09:41AM	Q3 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.89%
Nov-11-24 04:09PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance) +8.82%
04:02PM	Assertio Reports Third Quarter 2024 Financial Results (GlobeNewswire)
03:41PM	Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio (Business Wire)
07:30AM	Assertio Provides Response to Letter from Short-seller (GlobeNewswire)
Nov-08-24 09:00AM	Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud (Business Wire) -15.84%
07:06AM	Assertio Holdings Inc (ASRT) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Oct-30-24 08:00AM	Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 (GlobeNewswire)
Oct-09-24 05:18PM	Assertio Holdings Inc (ASRT) Q2 2024 Earnings Call Highlights: Navigating Sales Challenges and ... (GuruFocus.com)

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schlessinger Sam	EVP, General Counsel	Feb 21 '26	Option Exercise	0.00	1,143	0	15,248	Feb 24 06:02 PM
Patel Ajay	EVP and CFO	Feb 21 '26	Option Exercise	0.00	1,143	0	16,508	Feb 24 06:01 PM
Schwichtenberg Paul	President and COO	Feb 21 '26	Option Exercise	0.00	1,143	0	14,553	Feb 24 06:01 PM
Schlessinger Sam	EVP, General Counsel	Feb 18 '26	Option Exercise	0.00	2,778	0	15,344	Feb 20 06:01 PM
Schwichtenberg Paul	President and COO	Feb 18 '26	Option Exercise	0.00	2,778	0	14,787	Feb 20 06:00 PM
Patel Ajay	EVP and CFO	Feb 18 '26	Option Exercise	0.00	2,778	0	16,742	Feb 20 06:00 PM
Schlessinger Sam	EVP, General Counsel	Feb 07 '26	Option Exercise	0.00	1,389	0	13,185	Feb 10 06:27 PM
Schwichtenberg Paul	President and COO	Feb 07 '26	Option Exercise	0.00	1,666	0	12,834	Feb 10 06:27 PM
Patel Ajay	EVP and CFO	Feb 07 '26	Option Exercise	0.00	1,666	0	14,789	Feb 10 06:26 PM
Stark David Matthew	Director	Nov 10 '25	Sale	0.76	8,959	6,806	98,541	Nov 12 06:00 PM
DAVID STARK	Director	Nov 10 '25	Proposed Sale	0.76	8,959	6,806		Nov 10 04:07 PM
O'Grady Brendan P.	CEO	May 31 '25	Option Exercise	0.00	166,665	0	178,371	Jun 03 06:00 PM

CAI

Caris Life Sciences Inc

ASRT

Assertio Holdings Inc

Upgrade your Finviz experience